KeifeRx is an emerging clinical-stage biopharmaceutical company developing novel and optimized, low dose, orally delivered tyrosine kinase inhibitors (TKIs) for the treatment of multiple, high-need neurodegenerative and immune diseases.
| Website | https://www.keiferx.com/ |
| Employees | 8 (3 on RocketReach) |
| Founded | 2019 |
| Address | 1356 Beverly Rd 300, McLean, Virginia 22101, US |
| Phone | +1 703-790-5590 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+11 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Biopharmaceutical, Neurodegenerative Diseases, Targeted Therapy, Clinical Stage, Novel Therapies, Clinical Trials, Drug Development, Biotechnology, Pharmaceutical Research, Precision Medicine, Therapeutics, Disease Treatment |
| Competitors | CVS Health, UNITEDHEALTHCARE INSURANCE COMPANY, Walgreens, RITE AID, Scripps Health, Express Scripts, MedImpact Healthcare Systems, Inc., OPTUMRX PHARMACY, INC., PharmacyX, Humana Pharmacy, Inc. +29 more (view full list) |
Looking for a particular KeifeRx employee's phone or email?
Chris Hoyt is the CEO of KeifeRx.
3 people are employed at KeifeRx.
KeifeRx is based in McLean, Virginia.